Nitrile-Based Inhibitors Targeting both SARS-CoV‑2 Main Protease and Human Cathepsin L.
TL;DR
The rational design and synthesis of dual Mpro/CatL inhibitors derived from the previously reported leads SM141 and SM142 are described, identifying multiple dual-target inhibitors with nanomolar potency against both Mpro and CatL and potent antiviral activity as well as selective Mpro inhibitors with strong enzymatic activity.
Abstract
The SARS-CoV-2 main protease (Mpro) and host cysteine protease cathepsin L (CatL) are both attractive targets for antiviral intervention. Herein we describe the rational design and synthesis of dual Mpro/CatL inhibitors derived from the previously reported leads SM141 and SM142. Optimization focused on replacement of the acrylate ester warhead in SM141 and SM142 with a nitrile, modifying the P2, P3, and P4 capping groups, and variation of the P1 lactam ring size. In addition, conformational restriction was achieved through macrocyclization between the P1 and P4 side chains to enhance binding affinity. These efforts identified multiple dual-target inhibitors with nanomolar potency against both Mpro and CatL and potent antiviral activity as well as selective Mpro inhibitors with strong enzymatic activity. Targeting both a viral protease and a host factor may provide more durable antiviral efficacy by reducing susceptibility to resistance arising from viral evolution of Mpro.